A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Lymphocytes, Interleukin-2, Drug Therapy, Combination, AIDS Vaccines, CD4 Lymphocyte Count, Cell Division, HIV Core Protein p24, Anti-HIV Agents, HIV Therapeutic Vaccine
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Have completed at least 60 weeks of treatment on ACTG 328. Are willing to continue on their assigned ACTG 328 treatment until after they have completed 24 weeks on this substudy. Have a viral load less than or equal to 2,000 copies/ml. Exclusion Criteria Patients will not be eligible for this study if they: Have an active opportunistic (HIV-related) infection. Are pregnant or breast-feeding. Have taken or are taking certain medications that are prohibited.
Sites / Locations
- Univ. of Iowa Healthcare, Div. of Infectious Diseases
- NY Univ. HIV/AIDS CRS